Acetyl-11-Keto-Beta-Boswellic Acid Has Therapeutic Benefits for NAFLD Rat Models That Were Given a High Fructose Diet by Ameliorating Hepatic Inflammation and Lipid Metabolism
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Acetyl-11-keto-beta-boswellic acid (AKBA), a potent anti-inflammatory compound purified from Boswellia species, was investigated in a preclinical study for its potential in preventing and treating non-alcoholic fatty liver disease (NAFLD), the most common chronic inflammatory liver disorder. The study involved thirty-six male Wistar rats, equally divided into prevention and treatment groups. In the prevention group, rats were given a high fructose diet (HFrD) and treated with AKBA for 6 weeks, while in the treatment group, rats were fed HFrD for 6 weeks and then given a normal diet with AKBA for 2 weeks. At the end of the study, various parameters were analyzed including liver tissues and serum levels of insulin, leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-β), interferon gamma (INF-ϒ), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). Additionally, the expression levels of genes related to the inflammasome complex and peroxisome proliferator-activated receptor gamma (PPAR-ϒ), as well as the levels of phosphorylated and non-phosphorylated AMP-activated protein kinase alpha-1 (AMPK-α1) protein, were measured. The results showed that AKBA improved NAFLD-related serum parameters and inflammatory markers and suppressed PPAR-ϒ and inflammasome complex-related genes involved in hepatic steatosis in both groups. Additionally, AKBA prevented the reduction of the active and inactive forms of AMPK-α1 in the prevention group, which is a cellular energy regulator that helps suppress NAFLD progression. In conclusion, AKBA has a beneficial effect on preventing and avoiding the progression of NAFLD by preserving lipid metabolism, improving hepatic steatosis, and suppressing liver inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Inflammation - 46(2023), 5 vom: 01. Okt., Seite 1966-1980 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kachouei, Reza Ataei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.10.2023 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10753-023-01853-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358123232 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358123232 | ||
| 003 | DE-627 | ||
| 005 | 20240124231910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10753-023-01853-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM358123232 | ||
| 035 | |a (NLM)37310644 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kachouei, Reza Ataei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acetyl-11-Keto-Beta-Boswellic Acid Has Therapeutic Benefits for NAFLD Rat Models That Were Given a High Fructose Diet by Ameliorating Hepatic Inflammation and Lipid Metabolism |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.10.2023 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Acetyl-11-keto-beta-boswellic acid (AKBA), a potent anti-inflammatory compound purified from Boswellia species, was investigated in a preclinical study for its potential in preventing and treating non-alcoholic fatty liver disease (NAFLD), the most common chronic inflammatory liver disorder. The study involved thirty-six male Wistar rats, equally divided into prevention and treatment groups. In the prevention group, rats were given a high fructose diet (HFrD) and treated with AKBA for 6 weeks, while in the treatment group, rats were fed HFrD for 6 weeks and then given a normal diet with AKBA for 2 weeks. At the end of the study, various parameters were analyzed including liver tissues and serum levels of insulin, leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-β), interferon gamma (INF-ϒ), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). Additionally, the expression levels of genes related to the inflammasome complex and peroxisome proliferator-activated receptor gamma (PPAR-ϒ), as well as the levels of phosphorylated and non-phosphorylated AMP-activated protein kinase alpha-1 (AMPK-α1) protein, were measured. The results showed that AKBA improved NAFLD-related serum parameters and inflammatory markers and suppressed PPAR-ϒ and inflammasome complex-related genes involved in hepatic steatosis in both groups. Additionally, AKBA prevented the reduction of the active and inactive forms of AMPK-α1 in the prevention group, which is a cellular energy regulator that helps suppress NAFLD progression. In conclusion, AKBA has a beneficial effect on preventing and avoiding the progression of NAFLD by preserving lipid metabolism, improving hepatic steatosis, and suppressing liver inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMP-activated protein kinase (AMPK) | |
| 650 | 4 | |a Acetyl-11-keto-beta-boswellic acid (AKBA) | |
| 650 | 4 | |a Inflammasome | |
| 650 | 4 | |a Non-alcoholic fatty liver disease (NAFLD) | |
| 650 | 4 | |a Peroxisome proliferator-activated receptor gamma (PPAR-ϒ) | |
| 650 | 7 | |a acetyl-11-ketoboswellic acid |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.31 |2 NLM | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 650 | 7 | |a Fructose |2 NLM | |
| 650 | 7 | |a 30237-26-4 |2 NLM | |
| 650 | 7 | |a Peroxisome Proliferator-Activated Receptors |2 NLM | |
| 700 | 1 | |a Doagoo, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Jalilzadeh, Maral |e verfasserin |4 aut | |
| 700 | 1 | |a Khatami, Seyyed Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Rajaei, Shima |e verfasserin |4 aut | |
| 700 | 1 | |a Jahan-Abad, Ali Jahanbazi |e verfasserin |4 aut | |
| 700 | 1 | |a Salmani, Farzaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Pakrad, Roya |e verfasserin |4 aut | |
| 700 | 1 | |a Baram, Somayeh Mahmoodi |e verfasserin |4 aut | |
| 700 | 1 | |a Nourbakhsh, Mitra |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahifar, Mohammad-Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Abbaszadeh, Hojjat Allah |e verfasserin |4 aut | |
| 700 | 1 | |a Noori, Shokoofeh |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Mitra |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdavi, Meisam |e verfasserin |4 aut | |
| 700 | 1 | |a Shahmohammadi, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Karima, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation |d 1975 |g 46(2023), 5 vom: 01. Okt., Seite 1966-1980 |w (DE-627)NLM000293016 |x 1573-2576 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:5 |g day:01 |g month:10 |g pages:1966-1980 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10753-023-01853-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 5 |b 01 |c 10 |h 1966-1980 | ||